Ixekizumab
Interleukin Inhibitors
Sold as TALTZ
- Drug class
- Interleukin Inhibitors
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 12
Overview
Ixekizumab is an active pharmaceutical ingredient in the Interleukin Inhibitors group (L04AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 9 | May 22, 2026 |
| CA Canada | Health Canada | 2 | April 24, 2025 |
| EU European Union | EMA | 1 | April 23, 2026 |
GBUnited Kingdom· MHRA
9 products
Uses
Plaque psoriasis Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Paediatric plaque psoriasis Taltz is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.
1). Axial spondyloarthritis Ankylosing spondylitis (radiographic axial spondyloarthritis) Taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.
Non-radiographic axial spondyloarthritis Taltz is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C- reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
CACanada· Health Canada
2 products
Uses
Plaque Psoriasis TALTZ (ixekizumab) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Psoriatic Arthritis TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD).
, methotrexate). Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy. Non-radiographic Axial Spondyloarthritis TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have responded inadequately to, or are intolerant to conventional therapy.
1 Pediatrics Pediatrics (6 to <18 years of age): The safety and efficacy of TALTZ for the treatment of moderate-to-severe plaque psoriasis have been established in pediatric patients from 6 to less than 18 years of age. 3 Pediatrics and 14 CLINICAL TRIALS, Pediatric plaque psoriasis).
EUEuropean Union· EMA
1 product
Uses
Plaque psoriasis Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Paediatric plaque psoriasis Taltz is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.
1). Axial spondyloarthritis Ankylosing spondylitis (radiographic axial spondyloarthritis) Taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.
Non-radiographic axial spondyloarthritis Taltz is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Drug interactions
Known interactions involving Ixekizumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL553180003 · revised May 22, 2026
- [2]Health Canada (DPD) · 02455102 · revised April 24, 2025
- [3]European Medicines Agency · EMEA/H/C/003943 · revised April 23, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.